Sugi Predict

Sugi Predict / Compounds / SCHEMBL4773737

SCHEMBL4773737

SCHEMBL4773737

CC(C)(C)OC(=O)N1CCC(Cc2ccc(N)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ GPR119 Q8TDV5 8/20 0.48
▸ PTPN2 P17706 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ PTPN6 P29350 1/20 0.47
▸ NR1H2 P55055 1/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887590 0.92 KDM4E (0.47) KDM4EPKMALDH1A1NPC1MAPT
SCHEMBL3145386 0.90 KDM4E (0.52) KDM4EPKMMAPTGPR119PTPN2
SCHEMBL14783164 0.88 FAAH (0.51) KDM4EPKMALDH1A1NPC1MAPT
SCHEMBL16113579 0.88 GPR119 (0.61) KDM4EPKMMAPTGPR119TP53
SCHEMBL2250178 0.88 GPR119 (0.60) KDM4EPKMALDH1A1GPR119PTPN2
SCHEMBL12263494 0.88 KDM4E (0.53) KDM4EPKMGPR119PTPN2PTPN1
SCHEMBL578839 0.87 FPR2 (0.53) KDM4EPKMGPR119PTPN2PTPN1
SCHEMBL22532739 0.87 KDM4E (0.52) KDM4EPKMMAPTGPR119PTPN2
SCHEMBL4773466 0.87 TP53 (0.54) KDM4EPKMGPR119TP53
SCHEMBL3155704 0.87 STS (0.56) KDM4EPKMALDH1A1HTTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638433-A1 NAMPT MODULATORS Cytokinetics, Inc. (US) 2025-10-29 — — EP disclosed
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2025-03-13 — — US disclosed
US-12157735-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2024-12-03 — — US disclosed
US-20240279215-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED 2024-08-22 — — US disclosed
US-12049464-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
CN-118359600-A Aryl imidazolyl isoxazole compound as well as preparation method and application thereof 中国科学院广州生物医药与健康研究院 2024-07-19 — — CN disclosed
WO-2024137981-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED (US) 2024-06-27 — — WO disclosed
US-20240051953-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2024-02-15 — — US disclosed
EP-4259145-A1 ALK-5 INHIBITORS AND USES THEREOF Sumitomo Pharma Oncology, Inc. (US) 2023-10-18 — — EP disclosed
US-11746103-B2 ALK-5 inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-09-05 — — US disclosed
US-6596876-B2 Prostaglandin I2 inhibitors SYNTEX (U.S.A.) LLC 2003-07-22 — — US disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 — — US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 — — US disclosed
US-20030036655-A1 2-(substituted-phenyl)amino-imidazoline derivatives BLEY KEITH ROGER (US) 2003-02-20 — — US disclosed
CN-1390201-A cyclic amine compounds as CCR5 antagonists TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-01-08 — — CN disclosed
US-6472536-B1 SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN SYNTEX (U.S.A.) LLC 2002-10-29 — — US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 — — EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 — — WO disclosed
US-6184242-B1 2-(substituted-phenyl)amino-imidazoline derivatives SYNTEX USA (LLC) 2001-02-06 — — US disclosed
EP-0902018-A2 2-(Arylphenyl)amino-imidazoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279215-A1 NAMPT MODULATORS NAMPT, SIRT1, NNT KDM4E 1782/4885PKM 733/4885ALDH1A1 758/4885
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 KDM4E 2791/4885PKM 4190/4885ALDH1A1 3228/4885
US-12157735-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 KDM4E 2543/4885PKM 3635/4885ALDH1A1 4303/4885
US-12049464-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 KDM4E 2543/4885PKM 3635/4885ALDH1A1 4303/4885
US-20030036655-A1 2-(substituted-phenyl)amino-imidazoline derivatives GIPR, TBXA2R, GRK2 KDM4E 4134/4885PKM 2829/4885ALDH1A1 2682/4885
US-20240051953-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 KDM4E 2543/4885PKM 3635/4885ALDH1A1 4303/4885
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 KDM4E 2543/4885PKM 3635/4885ALDH1A1 4303/4885
US-11746103-B2 ALK-5 inhibitors and uses thereof ACVR1, ALK, ACVRL1 KDM4E 664/4885PKM 1286/4885ALDH1A1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.